Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDK060 in Adults With Charcot-Marie Tooth Type 1A (CMT1A)
NCT07140614Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Sep 2025
- Primary completion
- Feb 2028
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Charcot-Marie-Tooth disease type 1A (CMT1A) comparing EDK060 with Placebo (2 arms). Primary endpoint: Adverse Events at day 140. Started Sep 2025; status: recruiting.
02
Drugs
EDK060
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on NCT07140614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140614.